RxDoctor Payments Data

Rusti Hauge, MD

Psychiatry · Houston, TXNPI 1639124092

Payments from drug & device makers

$2,748in general payments, 2019–2025

Across 117 payments — averaging $23.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$548
  • Otsuka America Pharmaceutical, Inc.$325
  • Alkermes, Inc.$308
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$274
  • Teva Pharmaceuticals USA, Inc.$243
  • Neurocrine Biosciences, Inc.$223
  • plus $826 from 14 others

What the payments were for

  • Food & beverage$2,68898%
  • Education$602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,748 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$4,250
Medicare patients
14
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$101,703
AuvelityDextromethorphan Hbr/Bupropion17$21,094
VraylarCariprazine Hcl12$17,882
TrintellixVortioxetine Hydrobromide11$8,894
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine34$1,223
Escitalopram Oxalate82$1,018
Sertraline Hcl52$866
Mirtazapine58$817
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine15$785
Bupropion XlBupropion Hcl27$722
Quetiapine Fumarate63$678
Aripiprazole28$662
Buspirone Hcl45$632
Fluvoxamine Maleate12$606
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$223$101,70312 claims
Axsome Therapeutics, Inc.Auvelity$78$21,09417 claims
AbbVieVraylar$145$17,88212 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$98$8,89411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →